Hepatitis C

HCC Risk After HCV Direct-Acting Antiviral Treatment

HCC Risk After HCV Direct-Acting Antiviral Treatment

By

The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.

Update on Pediatric HCV: Screening, Treatment, and Other Considerations

Update on Pediatric HCV: Screening, Treatment, and Other Considerations

By

Experts discuss screening, treatment, and other considerations in pediatric HCV.

DAAs Effective for HCV in Patients With Thalassemia

DAAs Effective for HCV in Patients With Thalassemia

By

Researchers compared the safety and efficacy of sofosbuvir plus ledipasvir vs pegylated interferon and ribavirin for 12 weeks in patients with thalassemia major and hepatitis C virus genotype 1 or 4.

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

By

HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.

CDC: More Interventions Needed to Aid HCV Elimination Program in Country of Georgia

CDC: More Interventions Needed to Aid HCV Elimination Program in Country of Georgia

More interventions are needed to meet the target of hepatitis C virus elimination in the country of Georgia, defined as a 90% reduction in prevalence by 2020.

 HCV Treatment Administered by Non-Specialists Safe, Effective

HCV Treatment Administered by Non-Specialists Safe, Effective

Non-specialists, including primary care providers and nurse practitioners, safely and effectively administer direct-acting antiviral therapy for hepatitis C virus to patients seen in FQHCs.

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

By

The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.

Hepatitis C Virus Infection and Cardiovascular Disease Risk

Hepatitis C Virus Infection and Cardiovascular Disease Risk

By

Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and mortality.

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

By

Steatosis, hypertension, older age, obesity, and HIV are risk factors for liver fibrosis in African-Americans with chronic hepatitis C.

Improving Hepatitis C Screening With EHR-Based Prompts

Improving Hepatitis C Screening With EHR-Based Prompts

Using an electronic health record-based can improve HCV screening rates among baby boomers.

FDA Approves Pan-Genotypic Treatment for HCV

FDA Approves Pan-Genotypic Treatment for HCV

By

FDA has approved Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C virus.

New Treatment Options for Rheumatic Manifestations of HCV

New Treatment Options for Rheumatic Manifestations of HCV

By

Patients with HCV are at risk for several extrahepatic sequelae. Find out what they are and the new treatment options for managing HCV in patients with rheumatic symptoms.

Ledipasvir-Sofosbuvir Plus Ribavirin Offers Alternative in GT3 HCV

Ledipasvir-Sofosbuvir Plus Ribavirin Offers Alternative in GT3 HCV

By

Fixed-dose ledipasvir-sofosbuvir plus weight-based ribavirin may offer a treatment alternative in treatment-naïve patients with non-cirrhotic GT3 HCV.

FDA Approves Single-Tablet HCV Regimen

FDA Approves Single-Tablet HCV Regimen

By

The FDA approved Vosevi for the retreatment of adults with chronic hepatitis C virus genotypes 1-6.

DAA-Based Eradication of HCV Associated With Improved Glycemic Control

DAA-Based Eradication of HCV Associated With Improved Glycemic Control

Direct-acting antiviral treatment of hepatitis C virus improved glycemic control for patients with type 2 diabetes.

Management of HCV in Liver Transplant Candidates and Recipients

Management of HCV in Liver Transplant Candidates and Recipients

By

Expert insight from Leslie B. Lilly, MD, FRCPC, medical director of GI Transplantation from the Toronto General Hospital in Canada, about direct-acting antivirals in the management of hepatitis C virus in the liver transplantation setting.

EASL Raises Serious Concerns Over Cochrane Review of DAAs for HCV

EASL Raises Serious Concerns Over Cochrane Review of DAAs for HCV

By

The European Association for the Study of the Liver raises concerns over Cochrane Review of direct acting antivirals for hepatitis C virus.

HCV Cure Rates High in HIV Coinfection With Integrated Healthcare Program

HCV Cure Rates High in HIV Coinfection With Integrated Healthcare Program

For patients with HCV and HIV coinfection, treatment is effective with standardized nurse/pharmacist support at urban clinics.

Screening for Viral Hepatitis Recommended Before Biologics in RA

Screening for Viral Hepatitis Recommended Before Biologics in RA

By

The Turkish Society of Rheumatology proposed a guideline of hepatitis screening in patients with rheumatoid arthritis.

 Knowledge of HCV Transmission in Opioid-Dependent Pregnant Women

Knowledge of HCV Transmission in Opioid-Dependent Pregnant Women

By

Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of hepatitis C virus.

 High Rate of SVR Across All HCV Genotypes With Three-Drug Combo

High Rate of SVR Across All HCV Genotypes With Three-Drug Combo

A combination pill of sofosbuvir, velpatasvir, and voxilaprevir is nearly 100% effective in curing hepatitis C in patients whose disease returned after treatment with direct-acting antiviral agents.

Novel RNA Virus Detected With Next-Generation Metagenomic Sequencing

Novel RNA Virus Detected With Next-Generation Metagenomic Sequencing

Next-generation metagenomic sequencing can detect a new RNA virus, human hepegivirus-1.

Hepatitis C Virus Infection: A Risk Factor for Type 2 Diabetes?

Hepatitis C Virus Infection: A Risk Factor for Type 2 Diabetes?

By

Hepatitis C virus infection may increase the risk for type 2 diabetes, but whether a causal relationship exists is unclear. Screening for type 2 diabetes in this population may have important public health implications.

HBV Reactivation: A Safety Concern With DAA Use in HBV/HCV Coinfection

HBV Reactivation: A Safety Concern With DAA Use in HBV/HCV Coinfection

Hepatitis B virus reactivation has become a safety concern in patients with HBV and HCV coinfection receiving direct-acting antiviral agents.

Transplantation of HCV-Infected Kidneys Into Uninfected Patients Possible

Transplantation of HCV-Infected Kidneys Into Uninfected Patients Possible

Researchers evaluated the safety and efficacy of transplantation of kidneys from HCV genotype 1-viremic donors into HCV-negative patients, followed by elbasvir-grazoprevir (Zepatier) treatment.

Sharp Increase in Maternal HCV Infection in US

Sharp Increase in Maternal HCV Infection in US

Hepatitis C virus infections among pregnant women have nearly doubled between 2009 and 2014 in the United States according to the CDC.

HCV Infection Doubled in Reproductive-aged Women From 2006 to 2014

HCV Infection Doubled in Reproductive-aged Women From 2006 to 2014

Researchers found that there was a doubling in the number of reproductive-aged women with acute and past or present HCV infection in the National Notifiable Disease Surveillance System.

CDC: Rise in HCV Infections Tripled in Last 5 Years

CDC: Rise in HCV Infections Tripled in Last 5 Years

The CDC reports that new hepatitis C virus infections in the US have nearly tripled over 5 years.

Congressional Acts Pose Threat to National ID Health Initiatives

Congressional Acts Pose Threat to National ID Health Initiatives

By

Passage of the 2017 budget, along with congressional approval of the AHCA, leaves large holes in the funding of the proposed national approach to infectious disease control.

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

By

An investigational direct-acting antiviral treatment combination improves patient-reported outcomes in addition to sustained virologic response in patients with HCV, especially patients with cirrhosis.

Sign Up for Free e-newsletters